Skip to main content
Fig. 4 | Thrombosis Journal

Fig. 4

From: Lipoxin A4 analogue, BML-111, reduces platelet activation and protects from thrombosis

Fig. 4

BML-111 inhibits intracellular Ca2+ mobilisation. Fura-2 AM-loaded platelets (4 × 108 cells/ml) were treated with BML-111 (25 and 50 µM) or vehicle control (modified-Tyrode’s HEPES buffer) for 5 min, then stimulated with CRP-XL (0.25 µg/mL) or thrombin (0.05 U/mL) for 5 min. (a, c) Traces of cytosolic calcium mobilisation after stimulation with CRP-XL or thrombin. (b, d) Cumulative data of the peak intracellular Ca2+ levels were shown. Peak calcium levels achieved in the presence of vehicle control defines 100%. Fluorescent intensity was measured by a plate reader (with excitation at 340 and 380 nm and emission at 510 nm). Data represent the mean ± SEM (n = 4). *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001 were as calculated by One-way ANOVA.

Back to article page